Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 5 de 5
1.
Acta Neurol Belg ; 122(3): 703-707, 2022 Jun.
Article En | MEDLINE | ID: mdl-34476752

BACKGROUND: A growing number of Guillain-Barré syndrome (GBS) and Miller Fisher Syndrome (MFS) cases following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are reported. Nevertheless, this association is still debated, and pathophysiology remains unclear. METHODS: Between April and December 2020, in three hospitals located in Brussels, Belgium, we examined four patients with GBS following SARS-CoV-2 infection. RESULTS:  Neurological onset occurred 3 weeks after SARS-CoV-2 symptoms in all patients. Three patients presented with acute inflammatory demyelinating polyneuropathy (AIDP) and had negative anti-ganglioside testing: two suffered from a severe SARS-CoV-2 infection and had good clinical outcome after intravenous immunoglobulin (IVIG) treatment; one with mild SARS-CoV-2 infection had spontaneously favorable evolution without treatment. The fourth patient had critical SARS-CoV-2 infection and presented acute motor and sensory axonal neuropathy (AMSAN) with clinical features highly suggestive of brainstem involvement, as well as positive anti-ganglioside antibodies (anti-GD1b IgG) and had partial improvement after IVIG. CONCLUSIONS: We report four cases of SARS-CoV-2-associated GBS. The interval of 3 weeks between SARS-CoV-2 symptoms and neurological onset, the clinical improvement after IVIG administration, and the presence of positive anti-ganglioside antibodies in one patient further support the hypothesis of an immune-mediated post-infectious process. Systematic extensive antibody testing might help for a better understanding of physiopathology.


COVID-19 , Guillain-Barre Syndrome , Miller Fisher Syndrome , COVID-19/complications , Gangliosides , Guillain-Barre Syndrome/complications , Guillain-Barre Syndrome/etiology , Humans , Immunoglobulins, Intravenous/therapeutic use , Miller Fisher Syndrome/complications , Miller Fisher Syndrome/drug therapy , SARS-CoV-2
2.
Epileptic Disord ; 24(1): 203-207, 2022 Feb 01.
Article En | MEDLINE | ID: mdl-34806980

The role of neuroinflammation in epileptogenesis is extensively investigated, but short-term effects of seizures on established CNS pathologies are less studied and less predictable. We describe the case of a woman with previous recurrent episodes of focal cerebral haemorrhage of unknown cause who developed a pseudo-tumoural oedema triggered by provoked focal status epilepticus. A brain biopsy revealed that the underlying condition was primary angiitis of the CNS. Ictal-induced blood-brain barrier dysfunction allows the entry of water and inflammatory molecules that, in the context of CNS inflammatory diseases, may trigger a self-reinforcing process. Caution should be observed when tapering antiepileptic drugs in patients with such conditions.


Epilepsia Partialis Continua , Vasculitis, Central Nervous System , Epilepsia Partialis Continua/complications , Female , Humans , Recurrence , Vasculitis, Central Nervous System/pathology
4.
J Neurol ; 268(3): 751-757, 2021 Mar.
Article En | MEDLINE | ID: mdl-32734353

BACKGROUND: Evidence of immune-mediated neurological syndromes associated with the severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is limited. We therefore investigated clinical, serological and CSF features of coronavirus disease 2019 (COVID-19) patients with neurological manifestations. METHODS: Consecutive COVID-19 patients with neurological manifestations other than isolated anosmia and/or non-severe headache, and with no previous neurological or psychiatric disorders were prospectively included. Neurological examination was performed in all patients and lumbar puncture with CSF examination was performed when not contraindicated. Serum anti-gangliosides antibodies were tested when clinically indicated. RESULTS: Of the 349 COVID-19 admitted to our center between March 23rd and April 24th 2020, 15 patients (4.3%) had neurological manifestations and fulfilled the study inclusion/exclusion criteria. CSF examination was available in 13 patients and showed lymphocytic pleocytosis in 2 patients: 1 with anti-contactin-associated protein 2 (anti-Caspr2) antibody encephalitis and 1 with meningo-polyradiculitis. Increased serum titer of anti-GD1b antibodies was found in three patients and was associated with variable clinical presentations, including cranial neuropathy with meningo-polyradiculitis, brainstem encephalitis and delirium. CSF PCR for SARS-CoV-2 was negative in all patients. CONCLUSIONS: In SARS-Cov-2 infected patients with neurological manifestations, CSF pleocytosis is associated with para- or post-infectious encephalitis and polyradiculitis. Anti-GD1b and anti-Caspr2 autoantibodies can be identified in certain cases, raising the question of SARS-CoV-2-induced secondary autoimmunity.


COVID-19/complications , Nervous System Diseases/etiology , Nervous System Diseases/immunology , Adult , Aged , Aged, 80 and over , Antibodies/cerebrospinal fluid , COVID-19/cerebrospinal fluid , Delirium/etiology , Delirium/psychology , Encephalitis/etiology , Encephalitis/psychology , Female , Gangliosides/immunology , Humans , Leukocytosis/cerebrospinal fluid , Male , Membrane Proteins/cerebrospinal fluid , Middle Aged , Nerve Tissue Proteins/cerebrospinal fluid , Nervous System Diseases/cerebrospinal fluid , Neurologic Examination , Radiculopathy/etiology , Radiculopathy/psychology , Spinal Puncture
...